跳至主要内容
临床试验/EUCTR2022-002924-11-AT
EUCTR2022-002924-11-AT进行中(未招募)1 期

An observational study on the effect of L-ornithine-L-aspertate (LOLA) on the Flavonifractor abundance in the gut microbiome in liver cirrhosis - LOLAbiome

CBmed GmbH0 个研究点目标入组 55 人开始时间: 2023年1月26日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
CBmed GmbH
入组人数
55

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Liver cirrhosis (clinical/radiological/histological diagnosis)
  • Indication for LOLA use (covert or over hepatic encephalopathy, Grad 0-2))
  • Written informed consent
  • Age 18 -100 years
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 44
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 11

排除标准

  • Allergy to LOLA or its constituents, or to medications with a similar chemical structure (oral nutritional supplements are allowed when stable >/= 8 weeks before and during the study)
  • Recent (•Rifaximin or any other antibiotic therapy within the past 4 weeks
  • Intake of LOLA in the past four weeks before inclusion
  • Intake of L-dopamine
  • Renal insufficiency with a serum creatinine >3mg/dl
  • Hepatocellular carcinoma BCLC D under best supportive care
  • Inability to give informed consent
  • Pregnancy or breastfeeding
  • Participation in another interventional trial within the last 30 days

研究者

发起方
CBmed GmbH

相似试验

Study to test the effect of the drug... | 临床试验